目的 探討壯骨止痛膠囊聯(lián)合伊班膦酸鈉治療原發(fā)性骨質疏松癥的臨床療效。方法 選取2018年12月-2021年12月?？谑械谒娜嗣襻t(yī)院收治的86例原發(fā)性骨質疏松癥患者,隨機分為對照組(43例)和治療組(43例)。對照組患者靜脈滴注伊班膦酸鈉注射液,3 mg/次加入5%葡萄糖注射液250 mL中,滴注時間不少于2 h,每3個月注射1次。在對照組的基礎上,治療組口服壯骨止痛膠囊,4粒/次,3次/d。兩組連續(xù)服藥12個月。觀察兩組患者臨床療效,比較治療前后兩組患者癥狀好轉時間,骨密度(BMD),生活質量評分量表(SF-36)評分,血清炎性因子白細胞介素-6(IL-6)、Ⅰ型前膠原氨基端前肽(PINP)、胰島素樣生長因子-1(IGF-1)、腫瘤壞死因子-α(TNF-α)水平。結果 治療后,治療組臨床總有效率95.35%明顯高于對照組患者(81.39%,P<0.05)。治療后,治療組癥狀好轉時間均明顯早于對照組(P<0.05)。治療后,兩組患者BMD、SF-36評分均明顯升高(P<0.05),且治療組BMD、SF-36評分均明顯高于對照組(P<0.05)。治療后,兩組血清炎性因子IGF-1、PINP水平明顯升高(P<0.05),而IL-6、TNF-α水平明顯降低(P<0.05),且治療組這些指標水平明顯好于對照組(P<0.05)。結論 壯骨止痛膠囊聯(lián)合伊班膦酸鈉治療原發(fā)性骨質疏松癥效果確切,能有效提高機體骨密度含量,改善癥狀,減弱體內炎性反應,患者生活質量提高顯著。

Objective To explore the clinical study of Zhuanggu Zhitong Capsules combined with ibandronate sodium in treatment of primary osteoporosis. Methods Patients (86 cases) with primary osteoporosis in the Fourth People's Hospital of Haikou from December 2018 to December 2021 were randomly divided into control (43 cases) and treatment (43 cases) group. Patients in the control group were iv administered with Sodium Ibandronate Injection, 3 mg/time added to 5% glucose injection 250 mL, drip time more than 2 hours, once every 3 months. Patients in the treatment group were po administered with Zhuanggu Zhitong Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 12 months. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, bone mineral density, SF-36 scores, serum factor IGF-1, IL-6, TNF-α and PINP levels in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of 95.35% in the treatment group was significantly higher than that in the control group (81.39%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the scores of BMD and SF-36 in two groups were significantly increased (P < 0.05), and the scores of BMD and SF-36 in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of serum inflammatory factors IGF-1, and PINP was significantly increased, while the levels of IL-6, and TNF-α were significantly decreased in two groups (P < 0.05), and the level of these indexes in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Zhuanggu Zhitong Capsules combined with ibandronate sodium in treatment of primary osteoporosis is effective, which can effectively increase the bone mineral density, improve the symptoms, weaken the inflammatory reaction in vivo, and improve the quality of life of patients.

R977

海南省衛(wèi)生計生科研計劃項目(19A200104)